Compare Deutsche Bank AG (DB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Novo Nordisk A/S — how do they compare? Deutsche Bank AG trades at $33.63 (market cap $62.42B), while Novo Nordisk A/S trades at $38.12 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Deutsche Bank AG's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Novo Nordisk A/S for 116 Days on average.
| DB | NVO | |
|---|---|---|
Market Cap | $62.42B | $165.31B |
Volume | 2,918,760 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $41.56 | $63.98 |
52-Week Low | $28.37 | $35.29 |
Typical Hold Time | 80 Days | 116 Days |
Enterprise Value | $77.06B | $179.56B |
Dividend Yield | 3.46% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% amid concerns over Q3 investment banking revenue. The stock shows attractive valuation with P/E of 9.1 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B. Technical indicators signal bearish momentum with price near support at $33. Recent news highlights management's focus on 2028 targets and wealth management growth.
The outlook remains mixed - strong fundamentals and undervaluation present opportunity, but near-term headwinds in investment banking and bearish technicals suggest caution. Key risks include revenue volatility and European economic pressures, while analyst consensus leans neutral with 57.6% hold ratings.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
